Home | | Pharmaceutical Biotechnology: Fundamentals and Applications | Indirect Link PK/PD Models - Pharmacodynamics of Protein Therapeutics

Chapter: Pharmaceutical Biotechnology: Fundamentals and Applications : Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs

Indirect Link PK/PD Models - Pharmacodynamics of Protein Therapeutics

The concentration–effect relationship of many protein drugs, however, cannot be described by direct link PK/PD models, but is characterized by a temporal dissociation between the time courses of plasma concentration and effect.

Indirect Link PK/PD Models

The concentration–effect relationship of many protein drugs, however, cannot be described by direct link PK/PD models, but is characterized by a temporal dissociation between the time courses of plasma concentration and effect. In this case, plasma concen-tration maxima occur before effect maxima, effect intensity may increase despite decreasing plasma concentrations and may persist beyond the time drug concentrations in plasma are no longer detectable. The relationship between measured concentration and observed effect follows a counter-clockwise hysteresis loop. This phenomenon can either be caused by an indirect response mechanism (see next section) or by a distributional delay between the drug concentrations in plasma and at the effect site.


The latter one can conceptually be described by an indirect link model, which attaches a hypothetical effect-compartment to a pharmacokinetic compart-ment model (Fig. 12). The effect compartment addition to the pharmacokinetic model does not account for mass balance, i.e., no actual mass transfer is implemented in the pharmacokinetic part of the PK/PD model. Instead, drug transfer with respect to the effect compartment is defined by the time course of the effect itself (Sheiner et al., 1979; Holford and Sheiner, 1982). The effect-compartment approach, however, is necessary, as the effect site can be viewed as a small part of a pharmacokinetic compartment that from a pharmacokinetic point of view cannot be distinguished from other tissues within that compartment. The concentration in the effect compartment represents the active drug con-centration at the effect site that is slowly equilibrat-ing with the plasma, and is usually linked to the effect via an Emax model.

Although this PK/PD model is constructed with tissue distribution as the reason for the delay of the effect, the distribution clearance to the effect compart-ment can be interpreted differently, including other reasons of delay, such as transduction processes and secondary post receptor events.

 

The hypoglycemic effect of insulin has been modeled by this type of PK/PD model (Hooper, 1991; Woodworth et al., 1994). Figure 13 shows the mean serum concentration profile of insulin after a single SC injection of 10 U in 10 volunteers, and the correspond-ing effect measured as the glucose infusion rate to maintain an euglycemic state. Figure 14 shows the hysteresis in the concentration–effect relationship, and how a typical sigmoidal concentration–effect curve is obtained with the hypothetical effect con-centration using a one-compartment pharmacokinetic model with indirect link (Woodworth et al., 1994).



Study Material, Lecturing Notes, Assignment, Reference, Wiki description explanation, brief detail
Pharmaceutical Biotechnology: Fundamentals and Applications : Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs : Indirect Link PK/PD Models - Pharmacodynamics of Protein Therapeutics |


Privacy Policy, Terms and Conditions, DMCA Policy and Compliant

Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.